Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity-Reference-Cited by-同舟云学术

Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity

Published:2019-05-20 Issue:6 Volume:39 Page:2105-2152
ISSN:0198-6325
Container-title:Medicinal Research Reviews
language:en
Short-container-title:Med Res Rev

Author:

Paludetto Marie‐Noëlle¹²³,Puisset Florent¹²³,Chatelut Etienne¹²,Arellano Cécile¹²^ORCID

Affiliation:

1. Centre de Recherches en Cancérologie de Toulouse, INSERMUMR1037Université de Toulouse Toulouse Cedex 1 France

2. Faculté de PharmacieUniversité Paul Sabatier Toulouse France

3. Département PharmacieInstitut Claudius Regaud, IUCT‐O Toulouse France

Publisher

Wiley

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/med.21577

Reference158 articles.

1. FDA-approved small-molecule kinase inhibitors

2. Kinase-targeted cancer therapies: progress, challenges and future directions

3. Kinase inhibitors: the road ahead

4. Tyrosine kinase inhibitors: From rational design to clinical trials

5. Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The involvement of the Stat1/Nrf2 pathway in exacerbating Crizotinib-induced liver injury: implications for ferroptosis;Cell Death & Disease;2024-08-19

2. Use of Structural Alerts for Reactive Metabolites in the Application SpotRM;Chemical Research in Toxicology;2024-08-01

3. Higher risk of hepatotoxicity associated with cabozantinib in cancer patients;Critical Reviews in Oncology/Hematology;2024-04

4. Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors;Computers in Biology and Medicine;2024-01

5. Vascular endothelial growth factor receptor tyrosine kinase inhibitors associated hepatotoxicity: An Analysis of the FDA Adverse Event Reporting System;2023-10-17